OncoMatch/Clinical Trials/NCT07813208
Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival
Official title: Real-world Investigation of Diagnosis, Treatment, and Survival Status of Children With Ph+ ALL in China
Is NCT07813208 recruiting? Yes, currently enrolling (Oct 2026).
The study aims to conduct a real-world investigation of children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in China, assessing their diagnosis, treatment status, survival outcomes, and prognostic factors. The research will involve children diagnosed with Ph+ ALL between January 1, 2015, and December 31, 2024. Our objective is to understand the incidence and prognosis of CML-like ALL, compare the diagnostic and treatment differences between CML-like ALL and typical Ph+ ALL, and provide clinical evidence for standardized treatment of CML-like patients. Through a multicenter retrospective study, we hope to improve the diagnostic and treatment strategies for children with Ph+ ALL, enhancing patient survival rates and quality of life.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: ABL1 bcr-abl1 fusion
Demographics
Prior therapy
Must have received: BCR-ABL inhibitor (imatinib, dasatinib)
Standardized TKI therapy (imatinib, dasatinib, or other TKIs) was administered
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07813208 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received BCR-ABL inhibitor.
Does this trial require ABL1?
Yes, ABL1 bcr-abl1 fusion is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 18 years or younger and at least 0 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages